Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease

Launched by ASSIUT UNIVERSITY · Mar 7, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to study patients with hepatocellular carcinoma (HCC), a type of liver cancer that often develops in individuals with chronic liver diseases. The main goal of the trial is to compare two groups of patients: those with HCC caused by viral hepatitis (like Hepatitis B or C) and those with HCC who also have fatty liver disease related to metabolic issues, such as obesity or diabetes. By looking at the characteristics and survival outcomes of these two groups, researchers hope to gain insights that can improve treatment and care for patients at risk of HCC.

To participate in this study, individuals must be at least 18 years old and have a diagnosis of HCC. They should have a history of chronic Hepatitis B or C infection, or have fatty liver disease confirmed by medical imaging, along with at least one metabolic risk factor. Participants will have the opportunity to contribute to important research that may help improve understanding and treatment of liver cancer. The trial is not yet recruiting, but it aims to gather valuable information that could change how doctors approach HCC in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (≥18 years old) diagnosed with HCC based on radiological, histological (if needed), or biomarker criteria (e.g., elevated AFP).
• . Documented history of:
• • Chronic Hepatitis B virus (HBV) infection or Hepatitis C virus (HCV) infection.
• • MASLD defined as hepatic steatosis (≥5%) confirmed by FibroScan or abdominal ultrasound along with at least one metabolic risk factor (e.g., obesity, type 2 diabetes, hypertension).
• • Ability to provide informed consent
• Exclusion Criteria:
• • . Other causes of chronic liver disease (e.g., autoimmune hepatitis, hemochromatosis, Wilson's disease).
• • Patients with incomplete clinical or diagnostic data.
• • Presence of other malignancies.
• • Patients refuse to participate